Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2024-05-17 00:00:00 ET · period of report 2024-05-15 · accession 0001601830-24-000056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2024-05-15 | RXRX | Secora Michael | CFO | F - Tax | $10.01 | -12.0K | 1.22M | -1.0% | -$119.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2024-05-15 | F | D | 11,962 | $10.01 | 1,219,093 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $7.44 to $7.70 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |